The Role of Pharmacogenomics in Improving the Management of Asthma

Overview

Journal J Allergy Clin Immunol

Specialty Allergy & Immunology

Date 2010 Feb 18

PMID 20159237

Citations 14

Authors

Shamsah Kazani

Michael E Wechsler

Elliot Israel

Affiliations

Soon will be listed here.

Abstract

There is a large amount of interindividual variability in both therapeutic and adverse responses to asthma therapies. Genetic variability can account for 50% to 60% of this variability. Pharmacogenomics holds out the promise of allowing clinicians to prospectively choose therapies that have the greatest likelihood to be effective for individual patients and to avoid those that might have a high likelihood of producing adverse effects. In this article we review the principles of pharmacogenomic investigation. We explore the data developed from the early pharmacogenomic studies with the most common asthma therapies. Furthermore, we explore the potential use of pharmacogenomics, as well as caveats in interpreting such information.

Citing Articles

Asthma/Rhinitis (The United Airway) and Allergy: Chicken or Egg; Which Comes First?.

Warner J J Clin Med. 2020; 9(5).

PMID: 32423152 PMC: 7291147. DOI: 10.3390/jcm9051483.

Glucocorticoid-Induced Transcription Factor 1 (GLCCI1) Variant Impacts the Short-Term Response to Intranasal Corticosteroids in Chinese Han Patients with Seasonal Allergic Rhinitis.

Dai Y, Ni S, Wu F, Zhao X Med Sci Monit. 2018; 24:4691-4697.

PMID: 29981236 PMC: 6069539. DOI: 10.12659/MSM.908814.

Prototype of a Standards-Based EHR and Genetic Test Reporting Tool Coupled with HL7-Compliant Infobuttons.

Crump J, Del Fiol G, Williams M, Freimuth R AMIA Jt Summits Transl Sci Proc. 2018; 2017:330-339.

PMID: 29888091 PMC: 5961781.

The Variants in the 3' Untranslated Region of the Matrix Metalloproteinase 9 Gene as Modulators of Treatment Outcome in Children with Asthma.

Dragicevic S, Kosnik M, Divac Rankov A, Rijavec M, Milosevic K, Korosec P Lung. 2018; 196(3):297-303.

PMID: 29600353 DOI: 10.1007/s00408-018-0113-y.

Physicians' pharmacogenomics information needs and seeking behavior: a study with case vignettes.

Heale B, Khalifa A, Stone B, Nelson S, Del Fiol G BMC Med Inform Decis Mak. 2017; 17(1):113.

PMID: 28764766 PMC: 5540399. DOI: 10.1186/s12911-017-0510-9.

References

Szefler S, Phillips B, Martinez F, Chinchilli V, Lemanske R, Strunk R . Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005; 115(2):233-42. DOI: 10.1016/j.jaci.2004.11.014. View

Burchard E, Ziv E, Coyle N, Gomez S, Tang H, Karter A . The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med. 2003; 348(12):1170-5. DOI: 10.1056/NEJMsb025007. View

Carroll C, Stoltz P, Schramm C, Zucker A . Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest. 2008; 135(5):1186-1192. DOI: 10.1378/chest.08-2041. View

Wechsler M, Lehman E, Lazarus S, Lemanske Jr R, Boushey H, Deykin A . beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2005; 173(5):519-26. PMC: 2662935. DOI: 10.1164/rccm.200509-1519OC. View

Drazen J, Yandava C, Dube L, Szczerback N, Hippensteel R, Pillari A . Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999; 22(2):168-70. DOI: 10.1038/9680. View

Klotsman M, York T, Pillai S, Vargas-Irwin C, Sharma S, van den Oord E . Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007; 17(3):189-96. DOI: 10.1097/FPC.0b013e3280120043. View

Sampson A, Siddiqui S, Buchanan D, Howarth P, Holgate S, Holloway J . Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 2000; 55 Suppl 2:S28-31. PMC: 1765955. DOI: 10.1136/thorax.55.suppl_2.s28. View

Weiss S, Litonjua A, Lange C, Lazarus R, Liggett S, Bleecker E . Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J. 2006; 6(5):311-26. DOI: 10.1038/sj.tpj.6500387. View

Tantisira K, Small K, Litonjua A, Weiss S, Liggett S . Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet. 2005; 14(12):1671-7. DOI: 10.1093/hmg/ddi175. View

10.

Green S, Turki J, Bejarano P, Hall I, Liggett S . Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol. 1995; 13(1):25-33. DOI: 10.1165/ajrcmb.13.1.7598936. View

11.

Palmer L, Silverman E, Weiss S, Drazen J . Pharmacogenetics of asthma. Am J Respir Crit Care Med. 2002; 165(7):861-6. DOI: 10.1164/ajrccm.165.7.2109096. View

12.

Himes B, Wu A, Duan Q, Klanderman B, Litonjua A, Tantisira K . Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics. 2009; 10(9):1393-412. PMC: 2804237. DOI: 10.2217/pgs.09.93. View

13.

Martin A, Zhang G, Rueter K, Khoo S, Bizzintino J, Hayden C . Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma. J Asthma. 2008; 45(5):383-8. DOI: 10.1080/02770900801971792. View

14.

Hansen N, Brunak S, Altman R . Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther. 2009; 86(2):183-9. PMC: 2729176. DOI: 10.1038/clpt.2009.42. View

15.

Telleria J, Blanco-Quiros A, Varillas D, Armentia A, Fernandez-Carvajal I, Alonso M . ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med. 2008; 102(6):857-61. DOI: 10.1016/j.rmed.2008.01.011. View

16.

Green S, Turki J, Innis M, Liggett S . Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry. 1994; 33(32):9414-9. DOI: 10.1021/bi00198a006. View

17.

Bleecker E, Postma D, Lawrance R, Meyers D, Ambrose H, Goldman M . Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007; 370(9605):2118-25. DOI: 10.1016/S0140-6736(07)61906-0. View

18.

Stallings S, Huse D, Finkelstein S, Crown W, Witt W, Maguire J . A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics. 2006; 7(6):853-62. DOI: 10.2217/14622416.7.6.853. View

19.

Taylor D, Drazen J, Herbison G, Yandava C, Hancox R, Town G . Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000; 55(9):762-7. PMC: 1745862. DOI: 10.1136/thorax.55.9.762. View

20.

Tantisira K, Lima J, Sylvia J, Klanderman B, Weiss S . 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009; 19(3):244-7. PMC: 2731688. DOI: 10.1097/FPC.0b013e328326e0b1. View